Evidence map›Paper›PMID 39214577›Full record

ArticleBMJ case reports2024

Pulmonary pleomorphic carcinoma: current understanding illustrated through a case.

Tsering Dolkar, Kim Absher, Zhonglin Hao

Abstract readCase Reports
In one paragraph

Article in BMJ case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Tsering DolkarHospital Medicine, University of Kentucky, Lexington, Kentucky, USA.ORCID http://orcid.org/0000-0002-5638-1354
Kim AbsherPathology, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
Zhonglin HaoMedical Oncology, University of Kentucky, Lexington, Kentucky, USA zhonglin.hao@uky.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article describes a case of a man in his early 40s who was diagnosed with pulmonary pleomorphic carcinoma (PPC). PPCs are rare and aggressive forms of lung cancer. Chemotherapy is of limited efficacy. We present a case that has seemingly recurred shortly after adjuvant chemotherapy and immunotherapy following an R0 resection for localised disease. Biopsy however was negative for recurrence. PPCs may bear actionable mutations and tyrosine kinase inhibitors may be used when appropriate. Immunotherapy with or without chemotherapy is emerging as the mainstay for metastatic disease despite a lack of evidence from randomised clinical trials.

Indexed as

Lung NeoplasmsAdultCarcinomaChemotherapy, AdjuvantHumansImmunotherapyMaleNeoplasm Recurrence, LocalChemotherapyImmune Checkpoint InhibitorsLung cancer (oncology)

Identifiers

PMID39214577
PMCPMC12451873

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.